John Knox Village Of Pompano Beach Medicare and Medicaid Location: 700 Sw 4th Street, Pompano Beach, Florida 33060 Ratings: Phone: (954) 783-4001 |
Seaview Nursing And Rehabilitation Center Medicare and Medicaid Location: 2401 Ne 2nd Street, Pompano Beach, Florida 33062 Ratings: Phone: (954) 943-5100 |
Pompano Health And Rehabilitation Center Medicare and Medicaid Location: 51 W Sample Road, Pompano Beach, Florida 33064 Ratings: Phone: (954) 942-5530 |
Deerfield Beach Health And Rehabilitation Center Medicare and Medicaid Location: 401 East Sample Road, Pompano Beach, Florida 33064 Ratings: Phone: (954) 941-4100 |
Court At Palm Aire, The Medicare and Medicaid Location: 2701 N Course Dr, Pompano Beach, Florida 33069 Ratings: Phone: (954) 975-8900 |
Childrens Comprehensive Care Center Inc Medicare and Medicaid Location: 200 Se 19th Avenue, Pompano Beach, Florida 33060 Ratings: Phone: (954) 943-7638 |
News Archive
Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), announced the completion of its pivotal Phase III trial for prGCD, the Company's proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. The trial enrolled a total of 31 patients across Europe, North America, South America, Israel and South Africa. No serious adverse events were reported in this trial.
Researchers at the University of California, San Diego School of Medicine have identified an enzyme that controls the spread of breast cancer. The findings, reported in the current issue of PNAS, offer hope for the leading cause of breast cancer mortality worldwide.
Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of AvastinĀ® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.
The University of Ottawa has earned a total of 10 Canada Research Chairs (CRCs) covering a broad scope of subjects, from the exploration of disruptive impacts of stress on higher brain functions to the need to preserve Indigenous traditional cultural memories, and emerging computing technologies that pave the way to smart cities.
› Verified 1 days ago